Clinical-stage biopharmaceutical company Acelyrin Inc. in Woodland Hills has announced the appointment of Jazz Pharmaceuticals Chief Executive Bruce Cozadd to its board.
Cozadd co-founded Jazz Pharmaceuticals in 2003 and has helped the company attain a market capitalization of more than $9 billion. Jazz specializes in delivering oncological and neurological therapies.
Cozadd has gathered experience in research and development, manufacturing, finance, corporate planning, sales and marketing. He served as executive vice president, chief operating officer, and chief financial officer, at ALZA Corp. prior to his post at Jazz. ALZA was acquired by Johnson & Johnson in 2001.
“His success as a biopharma leader has given hope to patients around the world, and his perspectives will help Acelyrin build our capabilities, drive growth for our investors, and realize our vision of accelerating the development of life-changing medicines to help patients with serious diseases,” Dr. Shao-Lee Lin, Acelyrin’s co-founder and chief executive, said in a statement.
Cozadd is also a member of the board of Biotechnology Innovation Organization, where he serves on the Health Section Governing Board. He also serves on the boards of two non-profit organizations, The Nueva School, and SFJAZZ.
“I’m passionate about building companies where top talent can excel and work inclusively as a team dedicated to better patient outcomes,” Cozadd said in a statement. “I share Acelyrin’s values and am passionate about the patient-centric, highly collaborative culture it is building, and its particularly innovative science in immunology.”